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Background: Regadenoson (REG) a new selective A2a receptor agonist was approved as a pharmacologic vasodilator for stress myocardial 
perfusion imaging (SPECT). Pharmacokinetic studies suggest delayed clearance of REG in chronic kidney disease (CKD). Although no dosing 
adjustments have been recommended the safety of REG in large series of CKD patients remains unstudied 
Methods: We identified 301 consecutive Stage 3 to 5 CKD ( eGFR < 60ml/min, Grp 1) patients who underwent REG SPECT from Jan -June 2009. 
Grp 1were compared to 500 patients undergoing REG SPECT during the same time period with a eGFR >60 ml/min ( Grp2, control ). A standard 
400 microgram REG bolus was used and gated Tc-99m tetrofosmin SPECT done. Patient demographics, REG SPECT data, side effects and arrhythmia 
occurrences were evaluated. Continuous variable are expressed as mean ± SD and compared using the unpaired Student’s t test, whereas chi-
square testing was used for comparison of dichotomous variables. A p value < 0.05 was considered significant. 
Results: Grp 1 consisted of 291 patients with Stage 3-4 CKD and 10 patients with Stage 5 CKD not on dialysis. Although both groups were 
comparable by age, gender and ethnicity, Grp 1 had a significantly higher prevalence of diabetes, CAD, and EF < 50% (vs Grp 2 all p =< 0.05 ). 
However there were no differences in arrhythmias ( Grp1, 44% vs Grp 2, 39% , p=ns). Ninety nine percent of arrhythmias in CKD patients were 
PVC’s(131/132). There was a 0% incidence of any AV block . One patient had transient junctional rhythm. Aminophylline use was comparable ( 13 
% vs 12.8%, p=ns ). Grp 1 had a blunted heart rate response( 15.4 + 16.7% vs 23.9 + 20.5% , p=<0.001) and greater systolic blood pressure drop 
response( -7.9 + 20.9 mm hg vs -1+21.8, p=<0.001) compared to Grp 2. Transient headache was more in Grp 2 (13.6% vs 23.6%, p=<0.001). No 
adverse events were noted after REG SPECT or at 1 week. 
Conclusion: This first large series of 400 microgram dosing of REG SPECT in Stage 3-5 non dialysis CKD patients indicates very favorable safety 
profile of REG with excellent tolerability, minimal side effects and favorable hemodynamic responses compared to control group. REG SPECT can be 
safely performed in Stage 3 -5 CKD non-dialysis population.
